Get the Stockscreener App
13.44
5.92%
0.7725
Cvrx Inc stock is traded at $13.44, with a volume of 88,370.
It is up +5.92% in the last 24 hours and down -13.53% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$12.67
Open:
$12.88
24h Volume:
88,370
Relative Volume:
0.32
Market Cap:
$307.42M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-6.4012
EPS:
-2.1
Net Cash Flow:
$-40.45M
1W Performance:
-1.47%
1M Performance:
-13.53%
6M Performance:
+13.92%
1Y Performance:
-55.99%
1-Day Range:
$12.80
$13.79
1-Week Range:
$12.49
$13.79
52-Week Range:
$6.40
$30.62
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
13.48 | 307.42M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
113.57 | 196.18B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
359.75 | 137.26B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
89.61 | 131.64B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
80.33 | 102.43B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.20 | 43.66B | 6.60B | 4.16B | 490.10M | 6.93 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
State Street Corp Buys 27,071 Shares of CVRx, Inc. (NASDAQ:CVRX) - Defense World
Institutions own 39% of CVRx, Inc. (NASDAQ:CVRX) shares but private equity firms control 39% of the company - Yahoo Finance
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet? - Simply Wall St
Fmr LLC Has $30,000 Position in CVRx, Inc. (NASDAQ:CVRX) - Defense World
(CVRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
CVRx to Present at J.P. Morgan Healthcare Conference 2025Key Industry Event - StockTitan
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CVRx's SWOT analysis: barostim maker's stock faces reimbursement crossroads - Investing.com
FY2026 Earnings Estimate for CVRx Issued By William Blair - MarketBeat
What is William Blair’s Forecast for CVRx FY2026 Earnings? - Defense World
Learn to Evaluate (CVRX) using the Charts - Stock Traders Daily
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com Nigeria
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com
Evaluating CVRx: Insights From 6 Financial Analysts - Inkl
CVRx (NASDAQ:CVRX) Given New $22.00 Price Target at Canaccord Genuity Group - MarketBeat
Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team - MSN
Cantor Fitzgerald Increases Earnings Estimates for CVRx - Defense World
FY2024 EPS Estimates for CVRx Lifted by Cantor Fitzgerald - MarketBeat
Parkman Healthcare Partners LLC Has $6.02 Million Stock Position in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
PDT Partners LLC Acquires New Position in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx Insiders May Regret Not Buying More, Market Cap Hits US$377m - Simply Wall St
(CVRX) Trading Report - Stock Traders Daily
Paul Verrastro Sells 1,430 Shares of CVRx, Inc. (NASDAQ:CVRX) Stock - MarketBeat
CVRx chief marketing officer Paul Verrastro sells $19,416 in stock By Investing.com - Investing.com Nigeria
CVRx chief marketing officer Paul Verrastro sells $19,416 in stock - Investing.com
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
CVRx to Present at Piper Sandler 36th Annual Healthcare Conference in December | CVRX Stock News - StockTitan
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
CVRx’s Barostim Gains New CPT Codes - MPO-mag
(CVRX) Long Term Investment Analysis - Stock Traders Daily
International Assets Investment Management LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx: Impressive Top-Line Growth Seems Priced In - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of CVRx (CVRX) with Overweight Recommendation - MSN
CVRx (NASDAQ:CVRX) Stock Price Expected to Rise, Craig Hallum Analyst Says - MarketBeat
CVRx earns Medicare win for Barostim procedure - Mass Device
CVRx gains CMS payment classification for Barostim - Investing.com
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire
CVRx, Inc. (NASDAQ:CVRX) Position Decreased by Emerald Advisers LLC - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN
FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Nov 19 '24 |
Option Exercise |
5.14 |
2,500 |
12,852 |
3,305 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Nov 19 '24 |
Sale |
13.58 |
1,430 |
19,417 |
1,875 |
0.65%
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):